GLP-1 receptor agonists have demonstrated substantial benefits in managing type 2 diabetes and obesity, including improved blood sugar control , weight reduction, and lower cardiovascular risk in appropriate patients
When GLP-1s suppress your appetite, your nutrient intake can drop too
Speak with your prescribing physician to review your plan
Some patients lose substantially more, while others lose less or discontinue treatment because of side effects, cost, access, or inadequate response
In preclinical studies, ALCAR reduced oxidative damage markers (lipid peroxidation, oxidized nucleotides, nitrotyrosine) in aged rat brains, while LCAR did not, despite both compounds similarly increasing ambulatory activity and tissue carnitine levels.[5] ALCAR also decreased infarction size in stroke models, whereas LCAR showed no protective effect in vivo, though both were neuroprotective in vitro.[6] These differences likely reflect ALCARs ability to donate acetyl groups for acetylcholine synthesis, energy production, and neurotransmitter metabolism.[2][7] For cardiovascular and metabolic applications, the compounds appear more comparable
Combined these findings suggest the potential application of Ru(II)-OH as a catalyst for the transformation of GSH to GSSG